Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

RARE PHOTOS: Btai - The Real Truth

1 Top Penny Stock to Watch Now

This small-cap biotech is chasing a big breakthrough in 2026.

Barchart · Jan 17

BioXcel Seeks FDA Label Expansion For Schizophrenia Treatment

BioXcel Therapeutics Inc. (NASDAQ:BTAI) announced that its SERENITY At-Home Phase 3 trial of BXCL501—its sublingual dexmedetomidine film for acute agitation in bipolar disorder or schizophrenia—met its primary endpoint.

Benzinga · Aug 27, 2025

BioXcel Stock Surges 19% In After-Hours Trading: What You Need To Know

BioXcel Therapeutics Inc. (NASDAQ:BTAI) experienced significant after-hours momentum, jumping 19.09% to $6.24 in the after-hours trading session on Tuesday, as investors got ready for the release of important clinical trial results.

Benzinga · Aug 27, 2025

From analysis to the latest developments in health,
read the most diverse news in one place.

BioXcel Therapeutics (BTAI) Stock Is Surging Monday: What's Going On?

BioXcel Therapeutics Inc (NASDAQ:BTAI) shares are trading higher. The AI biopharmaceutical company on Monday announced positive meeting comments from the U.S. Food and Drug Administration (FDA).

Benzinga · Aug 18, 2025

BioXcel Therapeutics (BTAI) Stock Is Extremely Volatile Today: What's Going On?

Shares of BioXcel Therapeutics Inc (NASDAQ:BTAI) are trading higher Tuesday morning, reversing sharply following earlier weakness, after the company announced its financial results for the second quarter. Here’s what investors need to know.

Benzinga · Aug 12, 2025

Oaktree, Qatar Investment Inject $260M In BioXcel To Fund Commercialization Of Schizophrenia Med

BioXcel Therapeutics Inc (NASDAQ:BTAI) received strategic financing from Oaktree Capital Management and Qatar Investment Authority (QIA) for gross funding of $260 million. The Company will use the funding to support the commercial activities of Igalmi (dexmedetomidine) sublingual film indicated for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder.…

Benzinga · Apr 19, 2022

BioXcel BXCL701 Combo Therapy Shows Encouraging Response Rates In Prostate Cancer

BioXcel Therapeutics Inc (NASDAQ: BTAI) announced results from its ongoing Phase 2 trial of BXCL701 in metastatic castration-resistant prostate cancer (mCRPC) patients with either adenocarcinoma or small cell neuroendocrine carcinoma (SCNC) phenotype.

Benzinga · Feb 15, 2022

Read news from The Economist, FT, and more,
with one subscription

Coverage From

Organisations

FDA

7,651 stories

Qatar Investment Authority

Oaktree Capital Management

10 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.